Article

Frequent EPHA2 receptor mutations in cholangiocarcinoma disrupt receptor forward signaling supporting a tumor suppressor role

2025-02-28

Abstract excerpt

<h4>ABSTRACT</h4> EPHA2 is a receptor tyrosine kinase highly expressed in many cancers. By analyzing cancer patient databases for mutations in the EPHA2 coding sequence, we found that cholangiocarcinoma (a hepatobiliary cancer with dismal prognosis) exhibits a uniquely high incidence of EPHA2 mutations. To deUine the functional signiUicance of these mutations, we generated representative EPHA2 mutants and monitor...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 35c0a688-d061-54f3-9224-a2c3de329d32
DOI: 10.1101/2025.02.25.640198

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Frequent EPHA2 receptor mutations in cholangiocarcinoma disrupt receptor forward signaling supporting a tumor suppressor roleDOI 10.1101/2025.02.25.640198Read

Frequent EPHA2 receptor mutations in cholangiocarcinoma disrupt receptor forward signaling supporting a tumor suppressor role.Semantic proximity Read

Cancer somatic mutations disrupt functions of the EphA3 receptor tyrosine kinase through multiple mechanisms.Semantic proximity Read

Mutated EPHA2 is a target for combating lymphatic metastasis in intrahepatic cholangiocarcinomaSemantic proximity Read

Recurring EPHB1 mutations in human cancers alter receptor signalling and compartmentalisation of colorectal cancer cellsSemantic proximity Read

Recurring EPHB1 mutations in human cancers alter receptor signalling and compartmentalisation of colorectal cancer cells.Semantic proximity Read

Recurring <i>EPHB1</i> mutations in human cancers alter receptor signalling and compartmentalisation of colorectal cancer cellsSemantic proximity Read

Targeting extracellular and juxtamembrane FGFR2 mutations in chemotherapy-refractory cholangiocarcinomaSemantic proximity Read

Screening for tumor suppressors: Loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma.Semantic proximity Read

PTPN9 dephosphorylates FGFR2pY656/657 through interaction with ACAP1 and ameliorates pemigatinib effect in cholangiocarcinomaSemantic proximity Read

The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinomaSemantic proximity Read

EPHA2 MUTATIONS CONTRIBUTE TO CONGENITAL CATARACT THROUGH DIVERSE MECHANISMS.Semantic proximity Read

FGFR2 fusion protein-driven mouse models of intrahepatic cholangiocarcinoma unveil a necessary role for Erk signalingSemantic proximity Read